Liver Disease

Researchers also found an improvement in specialized blood markers focusing on inflammation, endothelial dysfunction, and albumin function in patients receiving weekly albumin injection.

Chronic liver disease and pancreatitis were among the digestive diseases with high increases in incidence and mortality since 2000.

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

Individuals who were homozygous carriers of the PNPLA3 I148M genetic variant and reported excessive drinking and obesity had a 17.5 to 30.1 higher risk of progression to liver disease complications.

Among individuals without metabolic-associated fatty liver disease (MAFLD), those with nonalcoholic fatty liver disease (NAFLD) had a higher risk of developing metabolic syndrome.

Urease-positive Streptococcus salivarius was the most significantly abundant gut microbiota in patients with HE.

Pichamol Jirapinyo, MD, MPH, director of bariatric endoscopy fellowship at Brigham and Women's Hospital, explains the implications of her study on the effects of endoscopic gastric plication on liver fibrosis in patients with nonalcoholic steatohepatitis (NASH).

Patients with hepatic encephalopathy (HE) often do not seek care until they are in critical condition, making an optimized emergency care process critical to reduce adverse prognosis and improve clinical symptoms.

A comprehensive review assessed the ways that proper nutrition could help reduce the adverse effects of hepatic encephalopathy in patients with hepatic encephalopathy.

Compared with the use of lactulose alone, rifaximin plus lactulose can provide additional benefits in terms of increased effectiveness rate and decreased mortality in patients with hepatic encephalopathy (HE).

A review of 6 studies on treatment options for hepatic encephalopathy found that many require further research before they can be recommended.

A new analysis found only 1 in 10 studies of inequities in liver cancer had a European focus or origin.

A recent study aimed to provide insight and guidance for managing graft-versus-host disease in patients after liver transplantation.

US adult outpatients with psoriasis have a greater risk of developing nonalcoholic fatty liver disease compared with those without the skin condition.

In this column, an endocrinologist discusses the growing problem of liver disease and new options at their disposal, including vibration-controlled transient elastography.

Chronic liver disease is on the rise and the burden is expected to increase in the future, both in the United States and around the world. These are the most-read articles about liver disease in 2021.

Two posters presented at The Liver Meeting evaluated nonalcoholic fatty liver disease (NAFLD)–associated hepatocellular carcinoma (HCC) to understand the burden and identify the risk for developing HCC.

Using the fatty liver index (FLI) to identify nonalcoholic fatty liver disease (NAFLD), researchers sought to understand the association between first-degree family members of patients with diabetes and NAFLD.

Two posters presented at The Liver Meeting identified the primary care coordinators for patients with nonalcoholic steatohepatitis (NASH) and areas of unmet need among specialists to provide optimal management.

Posters review how a patient’s neighborhood impacts access to the liver transplant waitlist and how Medicaid expansion improved waitlist mortality.

Guidelines recommend patients with nonalcoholic fatty liver disease (NAFLD) who are obese achieve 5% to 10% weight loss to prevent NAFLD progression.

Specifically, patients with nonalcoholic fatty liver disease (NAFLD) have a higher risk of developing heart failure (HF) with preserved ejection fraction, according to new research.

Authors of a review published in Hormones outlined the benefits of healthy eating and physical activity to prevent and improve non-alcoholic fatty liver disease.

Better risk stratification can help prioritize patients with hepatocellular carcinoma on the transplant waitlist who have higher risk disease.